gsh glutathione sigma (1500 MG) from 0.01 μ glutaredoxin and glutathione reductase Glutaredoxin-S2,

In the current study, administration of rotenone impaired muscular coordination and motor function as witnessed by decrease in mean speed, total distance traveled, and rearing frequency, as well as immobility time increase in OFT

(2000), Horm Res 53(Suppl 3), PubMed 10971106 Statistics from preclinical literature AOD-9604 = modified fragment of hGH 177191 + N-terminal Tyr (sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe), molecular weight 1815.1 Da Developed at Metabolic Pharmaceuticals (Australia) based on the work of professor Frank Ng (Monash University) in the 1990s Standard experimental dose in obesity clinical trials: 1 mg/day subcutaneously (Phase 2b, Heffernan et al.) Mechanism: stimulation of 3-adrenergic receptors in adipose tissue, increased lipolysis and fatty acid oxidation without activation of the hGH receptor (no IGF-1 increase) Phase 2b clinical trial (2007, 300 patients): weight reduction ~2.8 kg vs placebo over 12 weeks FDA status: NDI rejection (2014) as a dietary supplement

This effect enables healing of peptic ulcers, gastroesophageal reflux disease (GERD), Barretts esophagus, and Zollinger-Ellison syndrome, as well as the eradication of Helicobacter pylori as part of combination regimens

Park G, Matsuura T, Komatsu K, Ogawa T

doi: 10.1016/j.rbmo.2020.08.013